A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

Trial Profile

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Esaxerenone (Primary) ; Eplerenone
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ESAX-HTN
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 20 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top